Good day, and welcome to the InfuSystem Holdings Incorporated Reports fourth quarter and fiscal year 2023 financial results conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your touch-tone phone, and to withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Mr. Joe Dorame. Please go ahead, sir. Good morning, and thank you for joining us today to review InfuSystem's fourth quarter and year-end 2023 financial results, ended December 31, 2023. With us today on the call are Richard DiIorio, Chief Executive Officer, Barry Steele, Chief Financial Officer, and Carrie Lachance, President and Chief Operating Officer. After the conclusion of today's prepared remarks, we'll open the call for questions. Before we begin with prepared remarks, I would like to remind everyone, certain statements made by the management team of InfuSystem during this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Except for the statements of historical fact, this conference call may contain forward-looking statements that involve risks and uncertainties, some of which are detailed under "Risk Factors" in documents filed by the company with the Securities and Exchange Commission, including the annual report on Form 10-K for the year ended December thirty-first, 2022. Forward-looking statements speak only as of the date the statements were made. The company can give no assurance that such forward-looking statements will prove to be correct. InfuSystem does not undertake and specifically disclaims any obligation to update any forward-looking statements except as required by law. Now I'd like to turn the call over to Richard DiIorio, Chief Executive Officer of InfuSystem. Rich? Thank you, Joe, and good morning, everyone. Welcome to InfuSystem's fourth quarter 2023 earnings call. Thank you all for joining us today. I'll get things started this morning with an overview of the past year. 2023 was a great year for InfuSystem. We delivered strong organic growth of more than 14%, finishing the year with revenue of $125.8 million. It was our fifth consecutive year of record revenue and easily beat our guidance. We said at the start of the year that it would be an execution year, and I couldn't be more proud of what the team accomplished in 2023. The sustained momentum reflects our ability to focus and successfully execute on our strategic priorities while providing our patients and partners with the highest levels of service. With our 2023 results, I believe we validated both the continuing strength of our core businesses and the potential of the two big growth initiatives we announced or launched in 2022. First, in our core business. Oncology had another record year in 2023, with the success coming from market share gains and continued improvements in our revenue cycle execution. These factors combined to grow the therapy by 8%. Our core equipment rental business continues to do what it has always been good at doing, while beginning to take advantage of new opportunities emerging for us in acute care. The solid, strong performance and cash flows from our two core businesses support continued execution against our current two major growth initiatives, which are Biomed and wound care. First, Biomed, specifically around the master services agreement with GE, delivered approximately $10 million of revenue in 2023 and ended the year on a run rate of approximately $11.3 million. With the initial rollout nearly complete, our focus will now turn to driving efficiencies, a topic Carrie will address in a few minutes. Our second major growth initiative relates to the developing wound care opportunities under our joint venture with Sanara. Wound care revenue was up materially, coming in at $3.9 million in 2023, beating our expectations for the year and providing a nice ramp for the larger contributions we expect to see moving forward. Most of the revenue in wound care to date has been related to our negative pressure device leases, but in the second half of the last year, we started distributing, albeit a very small amount, Sanara's advanced wound care products into the market. We expect a gradual but steady ramp of the Sanara products as facilities convert to InfuSystem as their wound care DME provider and begin ordering third-party payer products and supplies through the JV. I'll talk to that more later on in the call, but I'd like to turn it over to Barry to discuss our Q4 and 2023 year-end results. Thank you, Rich, and thank you everyone on the call for joining us today. I'm going to focus on four topics. First, I'll talk about a change we made in the classification of some expenses on our income statement. Second, I want to share a general observation regarding our financial trends, driven by the additional biomedical services revenue. Third, I'll review the main drivers for the fourth quarter's results. And finally, I'll update you on our current financial position and how it changed during the quarter. During fiscal year 2023, we reviewed our cost classifications primarily related to pump service parts, accessories, and outside maintenance costs that were previously classified within general and administrative expenses. Based upon this review, we concluded that certain of these costs were direct costs that were more appropriately classified as cost of revenues. As a result, we have reclassified these costs within the income statement beginning in fiscal year 2021. These costs are now presented within cost of revenues as opposed to general and administrative expenses. The reclassification did not impact revenues, operating income, net income, or earnings per share. Additionally, the reclassification did not change any amount in our balance sheet or statement of cash flows. In conjunction with our annual audit, we are also reviewing our footnote disclosures relating to the application of Accounting Standards Update No. 2016-02, Leases, or Topic 842, also known as ASC 842. We expect that this review will lead us to changing some of our revenue recognition disclosures for the years 2021 through the current year, but is not expected to result in any changes to our previously released financial results. Due to the review, along with the reclassification of expenses I previously mentioned, we have requested additional time to file our annual report. Now, let me touch on our financial results for the period. Before I get into my normal line-by-line review, I'd like to touch on some general trend-related observations. During 2023, our revenue growth consisted largely of new revenue in biomedical services, and in particular, came as we ramped up the volume of devices covered under our service agreement with GE HealthCare. This business is different than our other businesses in some important ways, including having a lower gross margin than the average of our other businesses, which is more than mitigated by a much lower amount of SG&A expenses. In other words, the business dilutes our gross margin percentage, but is accretive to our operating margin and our operating margin percentage, or at least it will be once we fully absorb what we currently have as costs related to the ramp-up phase. What's more, other than incremental working capital, the biomedical services business does not require additional capital investment as it grows. That is, we do not have to purchase medical devices or other long-lived assets. The investment we made in this business came when we acquired two small biomedical companies back in 2021, and when we ramped our biomed teams in 2022 and 2023. Accordingly, as we increase our biomedical revenue, we also increase the overall capital efficiency of our business. Whereas our core business in oncology and pump rental are quite capital intensive, biomed is very capital light. As we look at the current year and quarterly results, we will see these impacts. Let me go on now to focus on the actual results. We finished the year strong, with net revenues for the fourth quarter of 2023 totaling $31.8 million, and representing a $2.9 million or 10% increase from the prior year. There were two primary drivers for this increase: higher revenue from the GE HealthCare contract of $1.9 million, and higher revenue in oncology of $1.6 million. On December 31, the annualized revenue run rate for devices onboarded to the GE contract stood at approximately $11.3 million. Lower equipment sales of $800,000, which was mainly due to an especially strong prior year comparison, partially offset the oncology and GE increases. Gross profit for the fourth quarter of 2023 was $16.7 million, which was $1.2 million or 8% higher than the prior year fourth quarter. This was mainly driven by the higher sales, but was partially offset by a lower gross margin percentage, which was 52.6% during the fourth quarter of 2023, down from 53.9% from the prior year. The year-over-year decrease was mainly due to the higher proportion of biomedical services revenue, which has a lower average gross margin and the related additional start-up costs for the GE HealthCare Biomedical Services contract. GE HealthCare start-up costs are estimated to have been about $900 thousand for the 2023 fourth quarter. While the amount of start-up costs has been higher than we originally planned, we expect these elevated amounts to dissipate over the next several quarters, and that our margin will approach our original estimates once we reach full ramp and circle past the first year of coverage for the onboarded devices. Selling, general, and administrative expenses for the fourth quarter of 2023 totaled $15.5 million, representing an increase of $1 million or 6.6% as compared to the prior year. Much of the increase represented additional commissions paid in relation to the higher revenue amounts during the quarter and higher short-term management incentive related to improved operating performance in 2023 as compared to 2022. Despite the increase in dollar amount, the ratio of selling, general, and administrative expenses to net revenue was 1.6% lower during 2023 as compared to the fourth quarter of 2022. As a result, as a result of these impacts, our Adjusted EBITDA was $6.2 million, or 19.4% of net revenue during the 2023 fourth quarter, which represented a $700,000 increase in amount from the prior year, when Adjusted EBITDA was $5.5 million, or 19%. Turning to a few points on our financial position and capital reserves. As we indicated during our previous couple of quarterly calls, our operating cash flow for the fourth quarter, totaling $4.7 million, increased sequentially for the third straight quarter and was slightly better than the prior year fourth quarter. This was due to a slower amount of growth in our working capital levels. Additionally, our net capital expenditures were a relatively low $1 million during the fourth quarter. This lower amount is partly related to much of our revenue growth coming from the less capital-intensive revenue sources, such as biomedical services, as I already mentioned, and also from initiatives that we have been pursuing to increase pump utilization, including reducing the number of lost pumps. We expect similar increased capital efficiency going forward, with most of the gains related to diversifying our revenue streams. Because of these factors, we continue to be positioned well to fund continued net revenue growth within the growing cash flow from operations, backed by significant liquidity reserves available from our revolving line of credit and manageable leverage and debt service requirements. Our net debt decreased by $3.6 million to $28.9 million during the 2023 fourth quarter, marking the third straight quarterly reduction. Our available liquidity totaled $45.4 million at the end of the quarter. The decrease in total debt and higher trailing four quarter adjusted EBITDA caused our ratio of total debt to adjusted EBITDA to decrease to 1.3 times at the end of the quarter, as compared to 1.59 times at the end of the 2022 fourth quarter. Our debt consists of borrowings on our revolving line of credit with no term payment requirements, nearly five years in remaining term, and with $20 million of the outstanding balance protected from increasing interest rates through an interest rate swap, having the same term. Now I'd like to turn the call over to Carrie to share some color on operations. Thanks, Barry, and good morning, everyone. I would like to cover two topics today. First, an update on our long-running initiatives in revenue cycle management. Second, I'll catch everyone up on the work under our GE MSA. Starting on revenue cycle, I hope there are some on today's call that remember back four or five years ago, when revenue cycle was a regular and important part of almost every earnings call. This is because within our patient services business unit, most of the revenue was third-party payer. That is, we provide our equipment and services through a hospital or clinic and then submit for payment from the patient's insurance payer. Third-party payer, or TPP billing, is not as straightforward as it sounds. First, before you can bill a payer, you need a contract. To date, we have more than 800 contracts, ranging from national big name insurers to small regional payers operating in remote parts of the country. Each payer requires compliance, not only with the terms of the contract, but also with their unique and particular billing procedures. Perfection is not always possible, particularly since the payers will work to find reasons why they don't have to pay. However, we have been working consistently on this, and our years of investment and effort are really paying off, making a material difference during 2023, both to revenue and improved profitability in our oncology business. These improvements will reap benefits for years to come, not just in oncology, but in all areas of third-party billing we do, whether for products we introduce ourselves or for those where we partner with others, such as wound care under our JV with Sanara. Turning to biomed. We expect to complete the initial onboarding of devices under the GE MSA in the current quarter. The total number of devices covered by the contract is always changing as GE adds or drops facilities and as the inventories within each facility change. But the current number of devices under the contract is approximately 220,000 devices. The original term of the MSA was three years, but we've already agreed to an extension. That said, both parties have the ability to opt out on reasonable notice if the contract stops working for them as expected or desired. From our perspective, GE seems very satisfied with our work and appears eager to expand the MSA to more devices and services. We are open to this, but our goal has never been to create an especially big biomedical services operation. The third-party Biomed initiative was started after an internal review confirmed it was an area of high return on investment. This due in part to Biomed requiring very little CapEx. As we already had significant biomedical resources for servicing our own equipment, we decided to leverage that and add a revenue stream that complemented our oncology and rental businesses by being less CapEx dependent. Reviewing the progress of the GE Biomed business since 2022 provides a great example of the three-part growth cycle we regularly describe. The nature of our business is such that in most cases, in order to drive material revenue growth, we must first invest. This is true whether the new business is in rental, where we have to buy a pump before we can rent it, or in Biomed, where we have to hire and train technicians before they can begin working and generating service revenue. The three-stage cycle in our business is where we invest first, grow second, and then harvest the value of the new business third. In 2022, in Biomed, we began the material investments involved in standing up the network of Biomed technicians that we needed to do the work awarded under the MSA. In 2023, we continued investing and also experienced the surge of revenue growth as our Biomed teams onboarded facilities and pumps. In 2024, we expect to be focused on harvesting the value of the new business. The third stage, the profit optimization stage, is the most important part of the cycle. Unlike the initial enabling investment, which generally occurs only once, the harvest phase repeats year after year. So we are incentivized to get it right, to focus on the process improvements that will maximize the returns and value creation from the business. When we are satisfied with our Biomed operations, we will look to begin leveraging the national network and the new reference account to resume growing the business. Our model was, and still is, to focus on high-value work that justifies concierge-level pricing. The GE MSA changed our thinking on the scale of Biomed opportunity, but it did not change the basis of our strategy. GE has allowed us to build a national biomedical services network, and this, together with a reference account, should elevate the opportunities we see... In the first half of 2024, we will focus on efficiencies and profitability, and in the second half of the year, we will determine what next steps are best for long-term value creation. Back to you, Rich. Thanks, Carrie. Before going to the Q&A, I'd like to specifically call out how InfuSystem is leveraging the skills we developed within our core businesses to empower new business opportunities. This evolution and diversification of our business started with the Cardinal relationship. Recall that it was Cardinal that approached us. They sought our help because they did not have the systems enabling the transition of wound care patients from the hospital to the home. So they came to InfuSystem with an opportunity to partner and try to win a share of a very large business opportunity. While Cardinal's plan did not achieve the level of success that they needed, it was our work with them that led directly to the current opportunity with Sanara. And again, it was Sanara that came to us. They saw that we have the payer contracts, clinical team, national presence, and TPP billing capabilities they require to execute on their wound care strategies. But even more than with Cardinal, Sanara is looking to leverage a whole platform of services InfuSystem can provide. The JV is a win for both partners. Sanara provides the advanced wound care products and business model, and InfuSystem provides its platform of specialty healthcare services that will handle much of the distribution and billing for those products. I've shared before that InfuSystem is regularly approached by other healthcare companies about opportunities to partner in ways where, like Cardinal and Sanara, they hope to leverage our existing platform of services. This could involve our existing distribution channels into oncology or our expertise in infusion. It could be utilizing our 24/7 patient hotline, our payer contracts, or our highly skilled revenue cycle teams. It could be about leveraging our ISO-certified Biomed services or our logistics capabilities. We continue to see in our reviewing and developing some of these opportunities, but as we said last year, there is currently more than enough for us to do, focusing on our current two major growth initiatives. Our focus right now is on advancing these existing opportunities by improving the profitability of the work we are doing under the GE MSA and by growing our wound care revenue via the steady expansion of activities under the JV with Sanara. Now I'd like to shift to our guidance portion of the call. In 2024, we expect to see our core businesses, Oncology and traditional DME sales and rentals, contributing low single-digit revenue growth and continued steady earnings and cash flow. In biomedical services, after a strong year of growth, the focus will be on harvesting and preparing the new national network for its next round of growth, which might start in the second half, but is more likely to have impact next year. In wound care, we expect a slow and steady build of products distributed into the third-party channel. We are now starting to scale with incremental opportunities under the JV emerging over the course of the year. As we look to 2024, we have built conservative assumptions into our full year guidance, with revenue growth estimated to be in the high single-digit range and our Adjusted EBITDA margin estimated to be in the high teens, exceeding the full year margin of 17.8% we saw in 2023. We will look to update and refine our guidance as we move through the year. We expect such updates will include and integrate some important technology upgrades we're looking to initiate later this year. One of InfuSystem's strengths is partnering with companies, such as GE and Sanara, is our technology integrations. These systems improve efficiencies, reduce costs, and increase the stickiness of our services. These integrations tie back into some much older systems we run internally, systems that we are developing plans to upgrade to modern standards, which will, of course, provide significant efficiency benefits to our internal processes. When we commence with the upgrade, it will be a multi-year program and will include converting over to new financial and ERP backbones. When our planning identifies an appropriate start date, we will be able to share what the expected costs will be for this year and next year. So in summary, the plan is simple. With our unwavering commitment to help people live longer and healthier lives, we will successfully enhance our market share within acute care and wound care, while remaining focused on operational excellence, which will lead to execution and expanded Adjusted EBITDA margins, both leading to solid long-term returns to our shareholders. Operator, we are now ready to begin the Q&A portion of the call. Thank you. We will now begin the question-and-answer session. To ask a question, you may press star, then one on your touchtone phone. If you're using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. At this time, we'll pause momentarily to assemble our roster. Again, to ask a question, please press star, then one. Our first question will come from Alex Nowak with Craig-Hallum. Please go ahead. Good morning, everyone. You know, a lot of great commentary there in the prepared remarks, but, you know, one piece that's, you know, been the core franchise for InfuSystem for years is the oncology franchise. And when I look through the numbers, it looks like the, you know, the core oncology business actually grew the most from a dollar term. I guess that shouldn't be too much of a surprise, but it still seems like there's a fair amount of growth still left in that business. So just curious, how are you thinking about that for, you know, this year, next year? How much further can that go? Yeah, good morning, Alex. That's a great question. So last year was, I would almost call it an exceptional year for that business, right? It was a good, perfect storm. As Carrie mentioned, on the revenue cycle side, that team just continues to kind of overperform every year, and especially in 2023, with their efficiencies and how quick they're able to collect, the dollars. And then the team went out and added a bunch of new accounts, too. So it was a nice combination that drove that number. I think it was about 8% for the year, the combination of the two. So do I expect to see that every year? No. Do I still kind of expect it to be more like 2%-5% on an average year, probably that's more realistic. You know, if we open up a few big accounts this year or next year, maybe that pushes back up to that number. But, it's tough to squeeze that kind of efficiency like we saw in 2023, kind of every year out of that business. But it's not impossible. I just, I wouldn't expect it every year. But it's obviously nice when it, you know, every% in that business is a big contributor for the company, obviously. Yeah, absolutely. Well, it makes sense. And then it's, you know, going back to the guidance, you know, candidly, it has been a choppy last couple of years, and the guide has obviously been a variety of factors that have led to that. Just the confidence in the guide, and maybe the question is really more of, you know, what is not included in the guidance, if by the end of the year, if XYZ gets added to it, you know, we're gonna reach a different level of growth performance? Well, we're just not—we're kind of—we're not being aggressive in any one spot, or any spot at all. I think, you know, whether it's oncology, our core businesses in oncology or device sales and rentals or even the new businesses, we're not looking down the, you know, into the future in the next few quarters and saying, "Okay, we think that's gonna happen. We're gonna stick that in our guidance." We're just not putting that in there. So it's not any one specific thing, Alex. It's more like, hey, if wound care really takes off and we get a couple more big customers and it's $2 million more, that'll obviously push the guidance up, and we'll go out and beat and raise at some point. If we continue with the efficiencies in oncology, we could raise. You know, pain, we didn't really mention on the call, but, you know, they're gonna add a good amount of growth this year, probably solid double digits. If they hit everything in their forecast, that'll help us, you know, grow the business faster. So all those factors are kind of on the back burner. We just wanna, you know, and we've talked about this a lot over the last couple of years, right? We overextended expectations in 2021 and 2022. We're not gonna make that mistake again. My hope is you see more of a 2023 year from now on, which is we're conservative up front. As the year goes and we get more and more visibility and more runway behind us, we can get more specific, and we hit our number every year. So I'd rather be a little more conservative coming out of the gate. I mean, it's only the middle of March. We only have January numbers in, so it's not like we have a lot to look at yet. But we're just being kind of conservative across the board. It doesn't mean that we're gonna go out, you know, that we don't have to get up and work hard every day to get to the high single digits in revenue numbers. But there is, there's always gonna be upside there, but I'm certainly not gonna put it in the guidance anymore, because if it doesn't happen, I wanna make sure you guys have the right expectations and, you know, we can go execute on what we tell you guys. Makes total sense. A question on pain, actually, that's a good segue there. And we didn't talk about it much in the prepared remarks, but the No Pain Act goes into effect in 2025. It expands access to non-opioids for pain care. How do you think about that benefiting the business maybe in twenty... you know, 2025, certainly, but is there gonna be an earlier effect because people need to get, need devices, essentially, and need to be ready for when that bill goes into effect? Yeah, that's a great question. So having been around the reimbursement world, collectively for, you know, probably 100 years as a leadership team, we're gonna see two effects. We will see that. We will see some people that are gonna get ahead of the reimbursement and wanna kind of open up as a new account sooner. That doesn't mean we'll see kind of significant revenue. They're not gonna call us today. They'll call us at the end of the year and say, "Hey, we want to prepare for the new reimbursement." The other side of that coin is that when the reimbursement comes, the floodgates don't necessarily open. It takes accounts a while to get used to the billing process, to understand what they have to bill, how they have to bill, what the reimbursement looks like. You know, the actual dollar value of the reimbursement isn't out yet, so that will be a driver, too. So you have some... You know, it's like any other bell curve, right? We're gonna have some early adopters at the end of this year. We'll have some late adopters that might wait till, you know, mid to end of 2025 or even in 2026, right? Until they see the reimbursement, not just see the number, but actually see the dollars come in. So, obviously, it's great news for the market. It's great news for patients and families, right? The government's finally putting something behind eliminating opioid use upfront. So that's all great news. It will definitely help InfuSystem. It will help all of us in the market. Yeah, our hope is we see something at the end of the year, and people start to get ahead of this because they should, and not just because of reimbursement, but obviously that'll drive behavior. You know, as we get towards the end of the year, if we start to see that coming in, we'll obviously give you guys line of sight into that if we see it. Okay, makes sense. And then just last question is a kind of a clarification around the 10-K delay. So is there gonna be... I got a couple of questions in here, but is it gonna be a restatement of prior periods? Is there gonna be a material weakness notice that shows up once the 10-K is filed? And is there any issues with debt, debt covenants with this delay? There should not be any issues with the covenants. We'll be able to make all of our reporting requirements. We're meeting our financial covenants for sure. As far as the other point, until we actually have the audit done, I don't really have the ability to say anything. Obviously, the reclassification is a change we already made and shared with you, but we still have to finish the audit to know clarity on the other issues. Okay, got it. Thank you for the update. Thanks, Alex. The next question will come from Jim Sidoti with Sidoti & Company. Please go ahead. Hi, good morning, and thanks for taking the questions. With, with respect to GE, do you have sufficient staff now to, to implement that contract fully, or are you still bringing people on? I think we're pretty much staffed up. You know, there's always ebbs and flows of the team, but we're in pretty good shape. I mean, Carrie, we're probably at 90%+ of the way there, right? Yep, that's correct. ... Okay, and can you give us a little more color on how you think the revenue build will be with Sanara? Do you think this, you know, something that starts in, you know, second, third quarter, and how fast do you think that ramps up? So we're gonna see. We're already seeing some revenue come in for their products. I think that the challenge will be the comps last year, kind of in wound care specifically, had the leases in last year, right? Which was almost $4 million, just south of 400-- $4 million. So, the Sanara products are going out the door today. That ramp will happen probably in a very, very steady, kind of gradual pace. By the end of this year, we should really be, it should really be kicking in as it starts to build on itself. It'll just be, you know, we'll give you guys clarity on, you know, future calls 'cause it'll be hard from a comp standpoint with the leases in there for 2023, 'cause those aren't gonna repeat to the level that we saw last year. So, the ramp is coming. It's already here. It will accelerate, you know, as we come out of this year and certainly into 2025. But if you're forecasting high single-digit growth, I assume you're, you know, I assume you're thinking that you'll get some leases in- Oh, yeah. - 2024 as well. Yeah. Leases will always be part of that business. You know, we had one really big customer last year that drove the majority of the lease revenue, so we don't expect that to repeat. But there'll always be, you know, some growth and some revenue coming in from leases every year. That hopefully is always the case. You know, replacing that one big customer, you know, makes it a little bit tough from a comp standpoint, but we do expect the business to grow year-over-year versus 2023. So even with the leases in the comp, we still expect growth in that business. and that includes, you know, the June and September quarters, which were particularly strong for you. You think you'll have year-over-year growth in those quarters as well? I haven't looked at it quarter to quarter. It'd be hard to say right now, Jim, if that's the case. I'd have to go back and look at how many... I know the leases were heavy in those two quarters, right? Second and third quarter. So I don't know if the year-over-year comparison will look great, but there should be sequential growth in kind of that core Sanara business every quarter. It's gonna be hard when you look, when you lump the leases in, in 2023. Yeah. Yeah. All right. When you look at equipment, when you look at our equipment sales and the leases, you really gotta look at it on a trailing twelve basis, 'cause we've always traditionally had large deliveries that made the quarters lumpy. So that won't change going forward. Okay. All right, thank you. Again, if you have a question, please press star then one. Again, that is star then one. This concludes our question and answer session. I would like to turn the conference back over to Mr. Richard DiIorio for any closing remarks. Please go ahead, sir. Thanks, Chuck. I want to thank everyone for participating on today's call, and we look forward to our first quarter call, when we will update on our results and the progress with this year's strategic priorities. Have a great day. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.